

STUDIEN & UMFRAGEN 2024

Stand: Mai 2024

KONTAKT

NOGGO Studiengruppe

Tel.: 030 403 6865 30

studies@noggo.de

AGO Studiengruppe

Tel.: 0611 8804 670

office-wiesbaden@ago-ovar.de

NOGGO

Nord-Ostdeutsche Gesellschaft
für Gynäkologische Onkologie e.V.



AGO STUDIENGRUPPE

OVARIAL-, TUBEN- & PERITONEALKARZINOM

Primärtherapie, rekrutierend

NOGGO ov32 – MAKEI V

Randomisierte, prospektive, multizentrische Studie bei Patientinnen mit extrakranialem malignem Keimzelltumor

NOGGO ov53 / ENGOT-ov62 – N-Plus

A Phase II randomized, open label non-inferiority study of Niraparib maintenance after 3 vs. 6 cycles of platinum-based chemotherapy in completely debulked advanced HRDpositive high-grade ovarian cancer patients in first line therapy

NOGGO ov54 – SCOUT-1

Prospective non-interventional Study to Collect real-world clinical and patient-reported Outcome data in ovarian cancer patients eligible for first-line platinum-based chemotherapy and intended for BRCA/HRD testing

AGO-OVAR 26 – MATAO

MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)

AGO-OVAR 27 – WoO

Window-of-opportunity Proof-of-concept, Non-randomized, Open-label Phase II Trial of Olaparib Given Alone (Cohort A) or in Combination With Durvalumab (Cohort B) Prior to Primary Debulking Surgery in Histologically Proven High-grade Epithelial Ovarian Cancer

AGO-OVAR 28 / ENGOT-ov57

Niraparib vs Niraparib in Combination With Bevacizumab in Patients With Carboplatinum-taxane Based Chemotherapy in Advanced Ovarian Cancer (A Multicentre Randomised Phase III Trial)

Rezidivtherapie, rekrutierend

SUPPORTIVE THERAPIEN

Primärtherapie, rekrutierend

NOGGO S18 – EMRISK

Risikovorhersage-Modell zu chemotherapieinduzierter Übelkeit und Erbrechen bei gynäkologischen Karzinomen

Rezidivtherapie, rekrutierend

NOGGO S15 – FraStrROC

Entwicklung und prospektive Validierung eines Frailty-Scores für chemotherapiebedingte Toxizität beim Ovarialkarzinom

Primär- / Rezidivtherapie, rekrutierend

NOGGO S19 – EXPRESSION VIII

Umfrage zur individuellen Wahrnehmung + Infostand bei „Low-grade“-Ovarialkarzinom und Borderlinetumor

NOGGO S20/ENGOT-gyn4 – EXPRESSION IX

Umfrage für Langzeitüberlebende mit gynäkologischen Tumoren

NOGGO S22/ENGOT-EN16 – EXPRESSION XI

IMPROVE: International Survey for Endometrial Cancer patients: perspective and expectation on therapy and quality of life

Geplante Umfragen

platinsensitiv

NOGGO ov44 – PERCEPTION

Phase-II-Studie zur Bewertung der Wirksamkeit von Pembrolizumab in Kombination mit einer platinbasierten Chemotherapie und als Erhaltungstherapie beim Low-grade-Ovarialkarzinom

ab 2. Linie

NOGGO ov45 – CAROLIN

Nicht-interventionelle Beobachtungsstudie zur Erfassung von Krankheits-, Patientinnen- und Behandlungscharakteristika bei Langzeitüberlebenden mit Eierstockkrebs

ab 1. Linie

NOGGO-ov55 / ENGOT-ov56 – DOVACC

A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer

ab 2. Linie

AGO-OVAR 2.34 – MIROVA

A randomized Phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha high recurrent ovarian cancer eligible for platinum-based chemotherapy

ab 2. Linie

AGO-OVAR 2.41 / ENGOT-ov58 – TEDOVA

Randomized Phase II study comparing neo-epitope based vaccine OSE2101 (TEDOPI®) with or without Pembrolizumab versus best supportive care as maintenance treatment in platinum-sensitive recurrent ovarian cancer patient with controlled disease after platinum-based chemotherapy

2.–3. Linie

platinresistent

NOGGO ov52 / ENGOT-ov51 – MITO33

Randomized Phase III trial on Niraparib-Dostarlimab vs physician's choice chemotherapy in recurrent, ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment: MITO 33 trial

2.–3. Linie

Rezidivtherapie, geplant

AGO-OVAR 2.46 / ENGOT-ov81 – RAMP 301

A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

platinsensitiv

NOGGO ov65 / ENGOT-ov79 – REFRaME-O1

A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) versus Investigator's Choice of Chemotherapy in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor alpha (FOLR1)

ab 2. Linie

NOGGO ov66 / ENGOT-ov82 – EvoPAR

A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, 3-cohort Study of Saruparib Second-line Maintenance Therapy in Patients with Platinum-Sensitive Relapsed Ovarian Cancer, who Progressed After First-line PARPi (EvoPAR-Ovarian01)

ab 2. Linie

NOGGO S30 – Expression XVIII

Angst vor Krisen vs. Angst vor Krebs – Internationale Umfrage zum Einfluss von Krisen auf Krebspatientinnen

NOGGO S33 – Expression XX

Breaking Bad News aus Sicht der Patientinnen

MAMMAKARZINOM

Primärtherapie, rekrutierend

NEUE STUDIE IN PLANUNG

ZERVIXKARZINOM, ENDOMETRIUMKARZINOM, UTERINE SARKOME & GYNÄK. TUMORE

Primärtherapie, rekrutierend

AGO-OP.6 – ECLAT

Pelvine und paraaortale LNE bei Patientinnen mit Endometriumkarzinom Stadium I oder II mit hohem Rezidivrisiko

Primär- / Rezidivtherapie, rekrutierend

NOGGO RU1 – REGSA NOGGO / AGO

Prospektive Registerstudie zur Erfassung der Behandlungspraxis von gynäkologischen Sarkomen in der klinischen Routine

Primär- / Rezidivtherapie, geplant

AGO-EN 7 / ENGOT-EN23 – MK-2870-005

A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)

AGO-VULVA 1 – PIERCE

Pembrolizumab in Combination With Lenvatinib in Patients With Recurrent, Persistent, Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy (PIERCE)

AGO-OVAR 2.44 / ENGOT-ov76 – GLORIOSA

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)

ab 2. Linie

platinresistent

NOGGO ov67 / ENGOT-ov83

A phase 2 study evaluating the efficacy and safety of torl-1-23 in women with advanced platinum resistant epithelial ovarian cancer (including primary peritoneal and fallopian tube cancers) expressing Claudin 6 (cldn6)

AGO-OVAR 2.45 / ENGOT-ov77 – REJOICE

A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

2.–4. Linie

NOGGO EN11 / ENGOT-EN20 – XPORT-EC-042

A Phase 3, randomized, placebo-controlled, double-blind, multicenter trial of Selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced or recurrent endometrial carcinoma

NOGGO EN13 / ENGOT-EN24 – DESTINY EC01

An Open label, Randomized, multicenter, Controlled, Phase III Study of First-Line Trastuzumab Deruxtecan (T-DXd) Monotherapy versus Carboplatin and Paclitaxel with or without Pembrolizumab in Patients with HER2-expressing (IHC 3+/IHC2+) Mismatch Repair Proficient (pMMR) Primary Advanced or Recurrent Endometrial Cancer

NOGGO cx10 / ENGOT-cx19 – eVOLVE

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)

NOTIZEN

TRANSLATIONALE FORSCHUNG

Primär- / Rezidivtherapie, rekrutierend

AGO-TR 2

Prevalence of somatic and germline mutations in patients with primary or relapsed endometrial carcinomas

Rezidivtherapie, rekrutierend

NOGGO TR2 – HELP-ER

nur 2. Linie

Retrospektive / Prospektive Studie zur Entwicklung des HELP-ER-Scores (verbessertes AGO-Score) anhand der Analyse / Identifizierung von Biomarkern wie HE4 + CA125 aus Blut und Tumorgewebeprobe als prädiktive Methode für die Resektabilität beim rez. Ovarialkarzinom

AGO-TR 3 – EXCYTE-1

Observational Analysis of the Association of Drug Activity Measured in Viable Tumour Tissues ex Vivo and Clinical Response in Ovarian Cancer: A Basic Research Study

Primär- / Rezidivtherapie, geplant

AGO-OP.11 – STREAM-I

Evaluation of preoperative clinical and translational selection criteria for cytoreductive surgery in endometrial cancer – A retrospective multicenter trial with an accompanying translational project